로딩 중…
지수 로딩 중…
이글벳
044960· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,925+0.34%
2026-11-02
Financials
Valuation Metrics
이글벳's Market Cap is ₩368B. At end of 2025 it was ₩529B. Ranked #1902 of 2,410 in KR market (top 79%), #1182 of 1,631 on KOSDAQ (top 72%), #201 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 36.79B KRW | KR#1,902/2,410 Sec#201/231 |
| Revenue | 44.73B KRW | KR#1,848/2,410 Sec#129/231 |
| Net Income | 5.45B KRW | KR#1,177/2,410 Sec#76/231 |
| Total Assets | 67.78B KRW | KR#2,035/2,410 Sec#172/231 |
| Net Assets | 54.68B KRW | KR#1,845/2,410 Sec#156/231 |
| Employees | 110 | KR#1,570/2,410 Sec#123/231 |
| Value | ||
| P/E | 6.78x | KR#612/2,410 Sec#27/231 |
| P/B | 0.68x | KR#1,175/2,410 Sec#65/231 |
| PEG | 0.12x | KR#463/2,410 Sec#23/231 |
| P/S | 0.83x | KR#1,324/2,410 Sec#74/231 |
| EV/EBITDA | 8.74x | KR#584/2,410 Sec#25/231 |
| Profitability | ||
| ROE | 9.97% | KR#617/2,410 Sec#43/231 |
| ROA | 8.05% | KR#438/2,410 Sec#33/231 |
| Op. Margin | 10.01% | KR#521/2,410 Sec#46/231 |
| Revenue Growth | 6.68% | KR#1,087/2,410 Sec#106/231 |
| Earnings Growth | 58.15% | KR#520/2,410 Sec#35/231 |
| Financial Health | ||
| Debt Ratio | 23.95% | KR#462/2,410 Sec#55/231 |
| Total Debt | 8.47B KRW | KR#1,671/2,410 Sec#154/231 |
| Cash | 6.11B KRW | KR#1,925/2,410 Sec#172/231 |
| Current Ratio | 3.67x | KR#428/2,410 Sec#65/231 |
| Net Debt/EBITDA | 0.53x | KR#678/2,410 Sec#41/231 |
| Dividend | ||
| Div. Yield | 2.74% | KR#767/2,410 Sec#40/231 |
| Div. Growth | 33.33% | KR#328/2,410 Sec#17/231 |
| Performance | ||
| 1Y Return | -30.77% | KR#1,458/2,410 Sec#113/231 |
| 1M Return | -5.03% | KR#803/2,410 Sec#84/231 |
| From 52W High | -39.57% | KR#712/2,410 Sec#47/231 |
| 1Y MDD | -38.56% | KR#513/2,410 Sec#36/231 |
| Trading | ||
| Volume | 18,963 shares | KR#1,239/2,410 Sec#124/231 |
| Trading Value | 55.3M KRW | KR#1,496/2,410 Sec#155/231 |
| Foreign Own. | 2.32% | KR#1,511/2,410 Sec#142/231 |
| Per Share | ||
| EPS | 431 KRW | KR#1,046/2,410 Sec#73/231 |
| BPS | 4,326 KRW | KR#1,617/2,410 Sec#116/231 |
Company Info
Iglobet, established in 1983, manufactures, imports, and sells animal pharmaceuticals for major livestock species, while also developing new businesses in pet pharmaceuticals, feed, and accessories. The company, which was listed on KOSDAQ in 2000, obtained EU GMP certification for sterile injectable drugs in 2017, establishing a foothold for European exports. It employs a sales strategy that shares profits with distributors through its SD policy. Iglobet is headquartered in Yesan-gun, Chungcheongnam-do.